Institutional members access full text with Ovid®

Share this article on:


Khatri, Pooja; Levine, Joshua; Jovin, Tudor

doi: 10.1212/01.CON.0000275640.84580.10

Despite the emergence of many promising therapies for use in acute ischemic stroke, IV recombinant tissue-type plasminogen activator (rt-PA) within 3 hours of stroke onset is currently the only available therapy proven to lead to better patient outcomes. Rapid thrombolytic therapy can substantially limit brain injury, and early rehabilitation can improve recovery after acute ischemic stroke. This chapter emphasizes the mechanics of emergent evaluation and administration of IV rt-PA. Acute rehabilitative interventions are also outlined.

Relationship Disclosure: Drs Khatri and Levine have nothing to disclose. Dr Jovin has received personal compensation for activities with CoAxia and Concentric Medical, Inc., and as associate editor of Journal of Neuroimaging.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Khatri discusses the unlabeled use of the Merci® device and intraarterial recombinant tissue-type plasminogen activator. Dr Levine has nothing to disclose. Dr Jovin has nothing to disclose.

© 2008 American Academy of Neurology
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website